期刊文献+

微管促解聚与促聚合药物序贯使用对肿瘤细胞的抑制作用 被引量:4

Inhibition Effect of Using Sequential Microtubule Depolymerization Drug and Polymerization Drug on Tumor Cells
下载PDF
导出
摘要 目的:探讨细胞微管促解聚与促聚合药物序贯使用对肿瘤细胞的抑制作用。方法:采用四唑盐(MTT)比色法,检测化疗药物紫杉醇和长春瑞滨对肿瘤细胞株MCF-7、SK-OV3、A549的抑瘤效应。设定紫杉醇组、长春瑞滨组、紫杉醇加长春瑞滨组、先紫杉醇4小时后加长春瑞滨组和先长春瑞滨4小时后加紫杉醇组,药物浓度为100%血浆峰值浓度(PPC),50%PPC,25%PPC,12.5%PPC,6.25%PPC,培养72小时测定。结果:对三种肿瘤细胞株MCF-7,SK-OV3,A549,先加长春瑞滨4小时后加紫杉醇组抑瘤效应均明显优于其他各组(P<0.01),先紫杉醇4小时后加长春瑞滨组抑瘤率并不优于其他组(P>0.1)。结论:在联合使用微管解聚或聚合的化疗药物时,先使用促解聚药物,再使用促聚合药物,对肿瘤细胞的抑制有增效作用。 Objective: To investigate the different inhibition effects of different using sequential of microtubule depolymeriza- tlon drug and polymerization drug on tumor cells. Methods: Three tumor cell lines including MCF-7 .SK-OV3.A549 were incubated with paclitaxel( FiX) and/or vinorelbine (NVB) of different concentrations. The cytotoxicity was examined by MTT test after incubation 72 hours. According to different drugs and different sequences added to 96-well tissue culture plates, 5 groups were divided: PTX group ( Group 1 ), NVB group ( Group 2), Frx plus NVB group ( Group 3), PTX first and plus NVB 4-hours-later group ( Group 4), NVB first and plus Frx 4-hour-later group ( Group 5). Drug concentrations were 100% peak plasma concentration ( PPC), 50% PPC, 25% PPC, 12.5% PPC,and 6. 25% PPC. Results: The inhibition effect on the three tumor ceil lines in Group 5 was stronger than those in the other four groups ( P 〈 0. 01 ). And the inhibition effect in Group 4 was not stronger than those in Group 1, Group 2 or Group 3 (P 〉 0. 1 ). Conclusion: Using microtubule depolymerization drug first and then using microtubule pdymerization drug have synergic inhibition effect on tumor cells.
出处 《肿瘤预防与治疗》 2008年第2期140-142,146,共4页 Journal of Cancer Control And Treatment
关键词 微管促解聚 微管促聚合 紫杉醇 长春瑞滨 序贯 肿瘤细胞 Microtubule depolymerization, Microtubule Polymerization, Paclitaxel, Vinorelbine, sequential, Tumor Cell
  • 相关文献

参考文献9

  • 1[2]Mario Airoldi,Luigi Cattel,Fuivia Pedani.Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer[J].Acta Oncologica,2003,42(3):186-194.
  • 2[3]Martin M,Lluch A,Casado A,et al,Paclitaxel plus vinorelbine:an active regimen in metastatic breast cacer patients with prior anthracycline exposure[J].Ann Oncol,2000,1:85-89.
  • 3陶苹,李志琳,李卉.长春瑞滨联合紫杉醇治疗晚期乳腺癌[J].中国癌症杂志,2006,16(1):61-62. 被引量:9
  • 4韩文兰,陈彩萍.紫杉醇联合诺维本治疗22例乳腺癌术后转移的疗效观察[J].中国医师杂志,2006,8(9):1281-1281. 被引量:2
  • 5[6]Gerasimos A.Docetaxel plus vinorelbine for previously treated ovarian cancer with platium and Paclitaxel[J].Proc Am Soc Oncol,2002,21:895.
  • 6官成浓,蔡良真,李姝君,罗海清,徐晓菲.多西紫杉醇联合盖诺治疗晚期非小细胞肺癌的临床观察[J].中国医院药学杂志,2006,26(8):989-990. 被引量:7
  • 7[8]Koletsky AJ,Guerra ML,Kronish L.Phase II study of vinorelbine and low-dose docetaxel in chemotherapy putic patients with hormone-refractory prostate cancer[J].Cancer J,2003,9(4):286-292.
  • 8[9]韩锐.肿瘤化疗预防与药物治疗[M].北京:北京医科大学中国协和医科大学联合出版社,1991:273-283.
  • 9[10]Manfredi JJ,Horwitz SB.Taxol,an antimitotic agent with a new mechanism of action[J].Pharmac Ther,1984,25:83.

二级参考文献9

共引文献16

同被引文献71

  • 1梁智,张伟.胶滴肿瘤药敏检测技术的研究进展[J].癌症进展,2005,3(5):442-448. 被引量:7
  • 2姚静,李小兰,李伟华,吴剑宏,谢大兴,龚建平.抗肿瘤药物敏感性实验方法的比较[J].中华实验外科杂志,2005,22(7):792-793. 被引量:7
  • 3Trudeau ME.Phase Ⅰ-Ⅱ studies of docetaxel as a single agent in the treatment of metastatic breast cancer[J].Semin Oncol,1999,26(3 Suppl 8):21-26.
  • 4Ravdin PM,Valero V.Review of docetaxel (Taxotere),a highly active new agent for the treatment of metastatic breast cancer[J].Semin Oncol,1995,22(2 Suppl 4):17-21.
  • 5Garcia-Conde J,Lluch A,Martin M,et al.Phase Ⅱ trial of weekly Ⅳ vinorelbine in first-line advanced breast cancer chemotherapy[J].Ann Oncol,1994,5(9):854-857.
  • 6Weber BL,Vogel C,Jones S,et al.Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer[J].J Clin Oncol,1995,13(11):2722-2730.
  • 7Bissery MC,Vrignaud P,Lavelle F.Preclinical profile of docetaxel (taxotere):efficacy as a single agent and in combination[J].Semin Oncol,1995,22(6 Suppl 13):3-16.
  • 8Budman DR,Calabro A.In vitro search for synergy and antagonism:evaluation of docetaxel combinations in breast cancer cell lines[J].Breast Cancer Res Treat,2002,74(1):41-46.
  • 9Meier CR,Ⅲiger HJ,Steder M,et al.Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment[J].Onkologie,2008,31 (8-9):447-453.
  • 10Polychemotherapy for early breast cancer:an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group[J].Lancet,1998,352(9132):930-942.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部